EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FGFR Testing in Metastatic Urothelial Carcinoma—Who, When, and How to Test

André Mansinho, José Carlos Machado iD, Cátia Faustino, Arnaldo Figueiredo, João Moreira Pinto, Nuno Vau, João Ramalho-Carvalho iD, Manuel R Teixeira iD

Cancers · 29.01.2026 · 18 (3) · 444

DOI: 10.3390/cancers18030444 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.01.2026. Verfasst von André Mansinho und 7 weiteren Autor:innen. Beteiligte Einrichtung: START Lisbon, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, 1649-035 Lisbon, Portugal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson Innovative Medicine Portugal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic urothelial carcinoma (mUC) is a lethal cancer with limited therapeutic options. Advances in genomic and transcriptomic research have deepened the understanding of mUC biology, leading to the identification of clinically relevant molecular alterations that represent potential actionable targets. This has broadened the treatment landscape of the disease to include novel agents, such as antibody–drug conjugates (e.g., enfortumab vedotin) and targeted therapies, including the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib. Genomic alterations in FGFR3 are well-established oncogenic drivers in bladder cancer and represent predictive biomarkers of response to FGFR-targeted therapies. The phase III THOR trial demonstrated the clinical benefit of erdafitinib in previously treated mUC patients harboring FGFR3 alterations and supported its subsequent approval by the European Medicines Agency. In this context, accurate molecular profiling is essential to guide patient selection for FGFR inhibitor therapy. Equally important is the standardization and timely implementation of FGFR3 testing in clinical practice to optimize treatment planning. This review addresses key considerations in FGFR3 testing in mUC and discusses how it can be routinely incorporated into clinical practice.

Schlagwörter

Stichwörter der Autor:innen

FGFR alterationbiomarkermetastatic urothelial carcinomamolecular testingprecision oncologytargeted therapy

Autor:innen und Institutionen

  • START Lisbon, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, 1649-035 Lisbon, Portugal.
  • GIMM-Gulbenkian Institute for Molecular Medicine, 1649-028 Lisbon, Portugal.
  • i3S-Instituto de Investigação e Inovação em Saúde, University of Porto, 4200-135 Porto, Portugal.
  • Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), 4200-135 Porto, Portugal.
  • Medical Faculty, University of Porto, 4200-319 Porto, Portugal.
  • Department of Medical Oncology, Instituto Português de Oncologia do Porto, 4200-072 Porto, Portugal.

ORCID-Profile: José Carlos Machado, João Ramalho-Carvalho, Manuel R Teixeira

Förderung

  • Johnson and Johnson Innovative Medicine Portugal

Zitieren

APA

Mansinho, A., Machado, J. C., Faustino, C., Figueiredo, A., Moreira Pinto, J., Vau, N., Ramalho-Carvalho, J., & Teixeira, M. R. (2026). FGFR Testing in Metastatic Urothelial Carcinoma—Who, When, and How to Test. Cancers, 18(3), 444. https://doi.org/10.3390/cancers18030444

Vancouver

Mansinho A, Machado JC, Faustino C, Figueiredo A, Moreira Pinto J, Vau N, et al. FGFR Testing in Metastatic Urothelial Carcinoma—Who, When, and How to Test. Cancers. 2026;18(3):444. doi:10.3390/cancers18030444

BibTeX
@article{Mansinho2026,
  author = {Mansinho, André and Machado, José Carlos and Faustino, Cátia and Figueiredo, Arnaldo and Moreira Pinto, João and Vau, Nuno and Ramalho-Carvalho, João and Teixeira, Manuel R},
  title = {FGFR Testing in Metastatic Urothelial Carcinoma—Who, When, and How to Test},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {444},
  doi = {10.3390/cancers18030444}
}
Kostenlos starten →